Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.18 ^USD	+1.87%		-2.68%	-85.49%

Mar. 22	Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Mar. 22	Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 22, 2024 at 04:02 pm EDT

Revelation Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 0.120254 million compared to USD 10.83 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 149.2 a year ago.

Latest news about Revelation Biosciences, Inc.

Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	Mar. 04	CI
Top Midday Decliners	Feb. 01	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings	Feb. 01	MT
Top Premarket Decliners	Feb. 01	MT
Top Premarket Gainers	Jan. 31	MT
Top Premarket Gainers	Jan. 29	MT
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury	23-10-12	CI
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla to Board of Directors	23-10-02	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Certain Warrants of Revelation Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2023.	23-05-13	CI
Certain Common Stock of Revelation Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2023.	23-05-13	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Revelation Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board	23-03-13	CI
Roth MKM Adjusts Price Target on Revelation Biosciences to $15 From $5, Maintains Buy Rating	23-02-14	MT
Revelation Biosciences Prices $15.6 Million Securities Offering; Shares Drop Fourth Consecutive Day	23-02-09	MT
Top Midday Decliners	23-02-09	MT
Revelation Biosciences Prices $15.6 Million Securities Offering; Shares Plunge	23-02-09	MT
Top Premarket Decliners	23-02-09	MT
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300	23-02-07	CI
Revelation Biosciences, Inc. announced that it has received $0.005 million in funding	22-12-18	CI

Chart Revelation Biosciences, Inc.

Duration

Period

More charts

Company Profile

Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.18 USD

Average target price

32.12 USD

Spread / Average Target

+1,373.62%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REVELATION BIOSCIENCES, INC.	-85.49%	3.56M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research